Syndax Pharmaceuticals, Inc.
SNDX
$20.08
-$0.33-1.62%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 375.88% | 589.36% | 538.71% | 1,866.34% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 397.28% | 628.88% | 597.19% | 2,133.71% | -- |
| Cost of Revenue | 10.17% | 9.75% | 8.23% | 41.19% | 44.88% |
| Gross Profit | 108.07% | 80.58% | 51.13% | 11.36% | -10.98% |
| SG&A Expenses | 26.91% | 48.61% | 58.30% | 67.08% | 78.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.84% | 22.60% | 24.11% | 43.16% | 47.16% |
| Operating Income | 34.90% | 19.63% | 4.44% | -17.75% | -30.56% |
| Income Before Tax | 26.50% | 10.42% | -4.99% | -26.96% | -37.76% |
| Income Tax Expenses | -33.33% | -33.33% | -- | -- | -- |
| Earnings from Continuing Operations | 26.56% | 10.46% | -4.89% | -26.85% | -37.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.56% | 10.46% | -4.89% | -26.85% | -37.64% |
| EBIT | 34.90% | 19.63% | 4.44% | -17.75% | -30.56% |
| EBITDA | 34.90% | 19.63% | 4.44% | -17.75% | -30.57% |
| EPS Basic | 27.68% | 11.63% | 0.45% | -15.38% | -19.97% |
| Normalized Basic EPS | 27.63% | 11.59% | 0.36% | -15.48% | -20.08% |
| EPS Diluted | 27.72% | 11.68% | 0.64% | -15.15% | -19.83% |
| Normalized Diluted EPS | 27.63% | 11.59% | 0.36% | -15.48% | -20.08% |
| Average Basic Shares Outstanding | 1.72% | 1.40% | 5.02% | 9.87% | 15.29% |
| Average Diluted Shares Outstanding | 1.72% | 1.40% | 5.02% | 9.87% | 15.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |